MarketCap
Facebook
X
Telegram
Merus N.V. Net Income | MRUS
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Merus N.V.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -215 M | -155 M | -131 M | -66.8 M | -85.5 M | -55.2 M | -27.8 M | -87.7 M | -49.7 M | -25.3 M | -21.2 M | -13.7 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -13.7 M | -215 M | -77.9 M |
Quarterly Net Income Merus N.V.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -95.5 M | -158 M | -96.5 M | - | -99.9 M | -50 M | -34.5 M | - | -23 M | -32 M | -39.7 M | - | -24.6 M | -5.71 M | -18.9 M | - | -14.9 M | -27.4 M | -10.2 M | - | -23.1 M | -18 M | -16.5 M | - | -9.27 M | -13.4 M | -7.08 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -5.71 M | -158 M | -39 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
14.5 M | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
-27 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Synthetic Biologics
SYN
|
-23.7 M | - | 1.32 % | $ 16.2 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
27.3 M | - | - | $ 2.02 B | USA |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M |  China |
 |
BioLineRx Ltd.
BLRX
|
-2.03 M | $ 2.6 | 5.56 % | $ 6.41 B |  Israel |
 |
Corner Growth Acquisition Corp.
COOL
|
-322 K | - | -0.89 % | $ 114 M | USA |
 |
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
BioMarin Pharmaceutical
BMRN
|
349 M | $ 64.67 | 0.11 % | $ 12.4 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Qilian International Holding Group Limited
QLI
|
-19.9 M | - | -6.08 % | $ 184 M | China |
 |
Happiness Biotech Group Limited
HAPP
|
-12.7 M | - | 1.35 % | $ 17.8 M | China |
 |
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17 M | - | -13.47 % | $ 169 M | France |
 |
CureVac N.V.
CVAC
|
162 M | - | - | $ 867 M |  Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-106 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-40 M | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
-8.5 M | - | - | $ 4.9 B |  Britain |
 |
Завод ДИОД
DIOD
|
37.2 M | - | - | - |  Russia |
|
Galera Therapeutics
GRTX
|
149 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.38 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Hepion Pharmaceuticals
HEPA
|
-8.28 M | - | -18.79 % | $ 39.3 K | USA |
 |
ARCA biopharma
ABIO
|
-105 M | - | 1052.0 % | $ 415 M | USA |
 |
MorphoSys AG
MOR
|
-190 M | - | 2.43 % | $ 254 M | Germany |
 |
Affimed N.V.
AFMD
|
-106 M | - | -34.95 % | $ 21.5 M | Germany |
 |
C4 Therapeutics
CCCC
|
-105 M | $ 3.85 | 0.12 % | $ 319 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-16.1 M | $ 23.78 | 1.13 % | $ 3.03 B | USA |
 |
Assembly Biosciences
ASMB
|
-6.12 M | $ 34.07 | 0.17 % | $ 382 M | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
-102 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
-40.9 M | - | - | $ 12.5 M |  Belgium |
 |
Adial Pharmaceuticals
ADIL
|
-7.98 M | $ 5.6 | 2.06 % | $ 3.74 M | USA |
 |
Codexis
CDXS
|
-44 M | $ 1.59 | 0.3 % | $ 139 M | USA |
 |
Generation Bio Co.
GBIO
|
-132 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Anika Therapeutics
ANIK
|
-10.9 M | $ 21.1 | 1.25 % | $ 303 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
3 M | - | -4.36 % | $ 27 M | USA |
 |
Gracell Biotechnologies
GRCL
|
-608 M | - | - | $ 3.37 B | China |
 |
Axsome Therapeutics
AXSM
|
-183 M | $ 199.02 | 0.31 % | $ 9.9 B | USA |
 |
GlycoMimetics
GLYC
|
154 K | - | 9357.83 % | $ 1.01 B | USA |
 |
AnaptysBio
ANAB
|
-13.2 M | $ 56.28 | 0.1 % | $ 1.62 B | USA |
 |
Aeterna Zentaris
AEZS
|
-10.4 M | - | 5.93 % | $ 314 M | Canada |
 |
AVROBIO
AVRO
|
-74.2 B | - | 1083.1 % | $ 745 M | USA |
 |
BeiGene, Ltd.
BGNE
|
287 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aytu BioScience
AYTU
|
-13.6 M | $ 2.25 | 0.45 % | $ 14.1 M | USA |
 |
AIkido Pharma
AIKI
|
-22.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
Aptose Biosciences
APTO
|
-25.5 M | - | -45.71 % | $ 1.2 M | Canada |